Spyre Therapeutics (SYRE)

• Market cap: $1.37B
• 1 day: -1.06%
• 5 days: -9.08%
• 1 month: -16.07%
• 3 months: -17.12%
• 6 months: -3.67%
• Year to date: 9.07%
• 1 year: 20.93%
• 5 years: -88.21%
• 10 years: -90.44%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.

Employees: 60

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

75% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 24

55% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 20

25% more capital invested

Capital invested by funds: $1.21B [Q2] → $1.51B (+$304M) [Q3]

10% more funds holding

Funds holding: 107 [Q2] → 118 (+11) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]

0.26% less ownership

Funds ownership: 101.16% [Q2] → 100.9% (-0.26%) [Q3]

53% less call options, than puts

Call options by funds: $18K | Put options by funds: $38K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $65 178% upside
• Avg. target: $65 178% upside
• High target: $65 178% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Baird Colleen Kusy 33% 1-year accuracy 7 / 21 met price target	178% upside $65	Outperform Maintained	13 Nov 2024
Guggenheim Yatin Suneja 29% 1-year accuracy 6 / 21 met price target	178% upside $65	Buy Maintained	25 Oct 2024